Oric Pharmaceuticals, Inc. ORIC Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$135.21M-1.8% | -$129.47M-1.3% | -$135.27M-12.8% | -$137.25M-23.9% | -$132.86M-30.6% | ||
| $1.19M+3.5% | $1.22M+10.2% | $1.2M+12.9% | $1.19M+12.6% | $1.15M+10.4% | ||
| $25.38M+16.4% | $25.04M+23.9% | $23.96M+26.6% | $23.39M+31.8% | $21.81M+31.6% | ||
| —— | —— | —— | —— | —— | ||
| -$1.68M+14.9% | -$1.79M-1,150% | -$1.03M-600% | -$1.88M— | -$1.98M— | ||
| -$110.88M+3.6% | -$110.97M+1.5% | -$116.54M-7.0% | -$120.23M-20.6% | -$115.01M-20.7% | ||
| $327K-75.9% | $712K-40.1% | $704K-31.4% | $1.09M+58.7% | $1.36M+79.3% | ||
| $413.13M+104% | $399.82M+58.7% | $389.16M+58.0% | $277.67M-8.4% | $202.19M-34.8% | ||
| —— | —— | -$122.36M— | —— | —— | ||
| $305.25M— | $244.37M— | —— | —— | —— | ||
| $306.39M+19,952% | $245.26M+93.8% | $244.34M+93.3% | $135.01M+6.9% | $1.53M-99.3% | ||
| $7.06M— | -$13.74M— | $5.44M— | —— | —— | ||
| $1.26M-81.4% | $2.3M-71.6% | $3.69M-57.0% | $5.05M-41.0% | $6.76M-10.3% | ||
| $1.19M+3.5% | $1.22M+10.2% | $1.2M+12.9% | $1.19M+12.6% | $1.15M+10.4% | ||
| -$1.68M+14.9% | -$1.79M-1,150% | -$1.03M-600% | -$1.88M— | -$1.98M— | ||
| —— | —— | —— | —— | —— | ||
| $3.39M— | $2.4M— | —— | —— | —— | ||
| -$111.2M+4.4% | -$111.68M+1.9% | -$117.25M-6.7% | -$121.31M-20.8% | -$116.37M-21.2% | ||
| -$111.2M+4.4% | -$111.68M+1.9% | -$117.25M-6.7% | -$121.31M-20.8% | -$116.37M-21.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Oric Pharmaceuticals, Inc. generate?
- Oric Pharmaceuticals, Inc. (ORIC) generated -$110.9M in operating cash flow over the trailing twelve months.
- What is Oric Pharmaceuticals, Inc.'s free cash flow?
- After $327.0K of capital expenditures, Oric Pharmaceuticals, Inc.'s free cash flow was -$111.2M over the trailing twelve months, up 4.4% year over year.
- Where does Oric Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.